Clovis Oncology, Inc., a biopharmaceutical company focused on commercializing anti-cancer agents, announced terms for its IPO on Monday. The Boulder, CO-based company plans to raise $130 million by offering 9.3 million shares at a price range of $13.00 to $15.00. At the mid-point of the proposed range, Clovis Oncology, Inc. will command a market value of $299 million. Clovis Oncology, which was founded in 2009, plans to list on the NASDAQ under the symbol CLVS. J.P. Morgan, Credit Suisse are the lead underwriters on the deal. The deal is expected to price the week of November 14.
Clovis Oncology follows in the footsteps of NewLink Genetics (NLNK) and is the second biotech company to announce terms in the two weeks.
